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Abstract 
Glioblastoma (GBM) is the most common form of primary brain tumour in adults and is 
essentially incurable.  Despite aggressive treatment regimens centred on radiotherapy, 
tumour recurrence is inevitable and is thought to be driven by GBM stem-like cells (GSCs) 
that are highly radioresistant.  DNA damage response pathways are key determinants of 
radiosensitivity but the extent to which these overlapping and parallel signalling components 
contribute to GSC radioresistance is unclear.  Using a panel of primary patient-derived GBM 
cell lines, we confirmed by clonogenic survival assays that GSCs were significantly more 
radioresistant than paired tumour bulk populations.  DNA damage response targets ATM, 
ATR, CHK1 and PARP-1 were upregulated in GSCs and CHK1 was preferentially activated 
following IR.  Consequently, GSC exhibit rapid G2/M cell cycle checkpoint activation and 
enhanced DNA repair.  Inhibition of CHK1 or ATR successfully abrogated G2/M checkpoint 
function, leading to increased mitotic catastrophe and a modest increase in radiation 
sensitivity.  Inhibition of ATM had dual effects on cell cycle checkpoint regulation and DNA 
repair that were associated with greater radiosensitising effects on GSCs than inhibition of 
CHK1, ATR or PARP alone.  Combined inhibition of PARP and ATR resulted in a profound 
radiosensitisation of GSCs which was of greater magnitude than in bulk populations and also 
exceeded the effect of ATM inhibition.  These data demonstrate that multiple, parallel DNA 
damage signalling pathways contribute to GSC radioresistance and that combined inhibition 
of cell cycle checkpoint and DNA repair targets provides the most effective means of 
overcome radioresistance of GSC. 
Word count: 247
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Introduction 
Glioblastoma (GBM) is the most common primary brain tumour in adults.  Despite optimal 
treatment consisting of surgical resection followed by radiotherapy with concomitant and 
adjuvant temozolomide chemotherapy, median survival remains dismal at 12–15 months (1). 
Responses to treatments are inevitably followed by relapse, typically within the maximally 
irradiated volume (2,3). In GBM tumourigenic cells display complex clonal dynamics in which 
genetically distinct sub-clones have variable serial repopulating activity in vivo (4,5). Such a 
functional readout is likely to represent activity of self-renewing GBM ‘stem-like’ cells (GSCs) 
whose competitive self-renewal ability varies on the basis of frequency and/or quantitative 
features and underpins the evolution of resistant disease (6). Consistent with this GSCs that 
express stem cell markers such as CD133, SSEA-1 (CD15), Nestin, SOX2 and Olig2 (7-10) 
are more resistant to radiotherapy and conventional chemotherapy than more differentiated 
epigenetically stable ‘tumour bulk’ cells (10-14).  Thus there is an urgent need to develop 
targeted treatment strategies that will overcome the innate resistance of GSCs, improve 
local tumour control and extend patient survival. 
Radiotherapy is a vital therapeutic modality for GBM which at a cellular level causes single 
and double stranded DNA breaks that evoke a multifaceted DNA damage response (DDR).  
At the apex of the DDR lie the serine/threonine protein kinases ataxia telangiectasia mutated 
(ATM) and ataxia telangiectasia and Rad3-related (ATR) which maintain genomic integrity 
by activating cell cycle checkpoints and DNA repair pathways (15).  ATM is mainly activated 
by DNA double-strand breaks (DSBs) whereas ATR responds to single-stranded regions of 
DNA generated at stalled replication forks  and during processing of DSBs by nucleases (16-
19).  The MRN (MRE11-RAD50-NBS1) complex has key roles in sensing and processing 
DSBs as well as activating ATM and ATR (20).   ATR activates cell cycle checkpoint kinase 
proteins including CHK1 whereas ATM functions primarily through activation of CHK2. 
These downstream checkpoint kinases activate G1 and G2/M cell cycle checkpoints through 
phosphorylation of phosphatases CDC25A, CDC25C and kinases CDK1 and Wee1 that 
regulate cell cycle progression (21).  Additionally, ATM promotes repair of a subset of DSBs. 
Poly(ADP-ribose) polymerase (PARP) facilitates repair of radiation induced single strand 
breaks (SSBs) and the radiosensitising effects of PARP inhibitors are well characterised 
(22).  This brief summary illustrates key components of the complex network of overlapping 
and parallel DDR pathways that dictates cellular outcomes after radiation treatment. 
There is growing evidence that DDR signalling is upregulated in GBM and integral to GSC 
radioresistance.   Analysis of GBM clinical samples has revealed high levels of p-ATM, p-
CHK1, p-CHK2 and PARP1 compared to normal brain tissue (23,24).  Furthermore, basal 
levels of p-CHK1, p-CHK2 and Rad17 have been shown to be higher in CD133+ GSCs 
compared to non-tumourigenic CD133- populations, a finding that was associated with  
radioresistance of the GSC population (10).  However, subsequent studies have either failed 
to show differences in DNA repair capacity based on CD133 status or revealed increased 
radiosensitivity of CD133+ GSCs compared to established GBM cell lines (25,26).  Such 
discrepancies may reflect methodological differences or comparisons between non-isogenic 
cell lines.  Indeed, we have recently demonstrated that radioresistance of GSC populations 
is associated with enhanced ATM dependent DSB repair proficiency (27). 
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Currently there is intense research into the development of small molecule inhibitors of DDR 
proteins (DDRi), one aim of which is to increase the therapeutic index of standard treatments 
(28).  This is driven by several factors: (i) DNA is the major target for many anticancer 
therapies, (ii) constitutive activation of DDR is frequently observed in cancers (29) and (iii) 
activation of DDR is associated with resistance to cytotoxic therapies. Several preclinical 
studies have successfully utilised DDRi to increase chemo- and radiosensitivity in GBM 
models but these results were not substantiated in the treatment resistant GSC population 
(30-34).  More recently we have shown the ATM inhibitor KU55933 to be a potent 
radiosensitiser of GSC (27) and inhibition of PARP has also been shown to overcome 
radioresistance of GSCs (35).  These findings corroborate and extend the landmark study by 
Bao and colleagues in which inhibition of CHK1 and CHK2 using debromohymenialdisine 
was shown to enhance the radiosensitivity of GSCs (10).   
The observation that GSCs exhibit upregulated DDR signalling provides both opportunities 
and challenges. Whilst targeting individual components of this complex network can increase 
the radiosensitivity of GSC, the relative contributions of these components and the 
implications of multiple DDR pathways and mechanisms contributing to radioresistance 
remain unexplored.  We addressed this by utilising paired, primary, patient derived GBM cell 
lines cultured to enrich for or deplete the GSC population (‘GSC’ and ‘bulk’ populations 
respectively).  We show that GSCs express higher total and activated levels of DDR targets 
than bulk populations and that this phenotype is maintained in orthotopic xenograft models 
and GBM patient specimens.  Our mechanistic studies highlight rapid activation of cell cycle 
checkpoint and enhanced DNA repair as key determinants of GSC radioresistance.  We 
show that, although selective inhibition of either pathway increases radiosensitivity of GSC, 
effects are limited by reciprocity between these signalling conduits.  Accordingly, combined 
inhibition of ATR and PARP1 significantly enhanced the radiosensitivity of GSCs, and the 
magnitude of this effect was greater than in bulk populations. We propose that targeting of 
parallel DDR pathways is required to maximise radiosensitisation of GSCs and optimise 
outcomes for GBM patients. 
Word count: 867
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Materials and Methods 
Derivation and maintenance of primary and patient derived GBM cell lines 
Primary patient derived GBM cell lines E2, G7, R10, R15 and R24 were derived from freshly 
resected tumour specimens and maintained as described previously (22,36).  Patient 
consent was sought before surgery and tissue collection was approved by the local regional 
Ethics Committee (LREC ref 04/Q0108/60) and compliant with the UK Human Tissue Act 
2004 (HTA Licence ref 12315).  Each cell line was cultured in pairs either on Matrigel TM (Life 
Technology) coated flasks in AdvDMEM F12 medium (Gibco) supplemented with 1% B27 
(Invitrogen), 0.5% N2 (Invitrogen), 4µg/ml heparin, 20ng/ml bFG, 20ng/ml EGF (Sigma), and 
1% L-Glutamine to maintain the GSC population or in MEM (Gibco) supplemented with 10% 
FBS Sigma, 1% L-glutamine and 1% sodium pyruvate to deplete the GSCs and generate a 
differentiated tumour bulk population.  All cell cultures were maintained at 370C, 5% CO2.  
Cell lines were utilised between 6-15 passages and then discarded.   
Generation of orthotopic tumours and immunohistochemistry 
Tumours were generated by injecting 1 x 105 cells in CD1 nude mice as described 
previously (37), and in supplementary materials and methods.   Immunohistochemistry was 
performed on paraffin embedded sections.  Following antigen retrieval sections were 
incubated with anti-Ki67, PARP-1 or p-ATM antibodies overnight followed by incubation with 
secondary antibodies.  Staining was visualised by application of DAB. 
Drug treatment and radiation 
ATM inhibitor KU-55933 (Tocris bioscience), ATR inhibitor VE821, PARP inhibitor olaparib, 
CHK1 inhibitors SCH900776 and CHIR-124 (Selleckchem), hydroxyurea and aphidicolin 
(Sigma) were all dissolved in DMSO.  For drug-radiation combination studies, cells were 
exposed to fresh media containing the inhibitor or relative DMSO control for 1 hour prior to 
irradiation in tissue culture vessels using an XStrahl RS225 cabinet at room temperature 
with 195kV/15mA X rays producing a dose rate of 1.6 Gray per minute.  For UV studies, 
media containing the drug was removed after one hour and cells were irradiated using a UV 
Stratalinker (Stratagene). 
Clonogenic and neurosphere assays 
Paired GSC and bulk population from E2 and G7 cell lines formed countable colonies and 
were seeded at a density of 250 cells per well in Matrigel coated 6 well dishes for 24 hours.  
Wells were treated with the inhibitors or relative DMSO control for 1 hour followed by mock 
or 1-5Gy irradiation. Cells were then incubated for a further 24 hours followed by 
replacement with fresh media. E2 and G7 colonies were fixed after 2 or 3 weeks respectively 
in methanol followed by staining with crystal violet.  Colonies consisting of minimum 50 cells 
were counted manually and using an automated colony counter (GelCountTM, Oxford 
Optronix).  Clonogenic survival data were fitted using a linear quadratic model and SER0.37 
and SF4Gy values were calculated from the fitted curve.  ANOVA test was used to analyse 
differences between clonogenic survival curves. 
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For neurosphere assay 10 GSCs were seeded into each well of a 96 well plate in 100µL 
medium containing the drug or relative DMSO control for 1 hour followed by mock or 2Gy 
irradiation.  48 hours later a further 150 µL of fresh media was added per well. Neurospheres 
were manually counted under 5x magnification after 3 or 4 weeks for G7 and E2 GSC 
respectively.  
Immunofluorescence 
Paired bulk and/or GSCs were plated on coverslips coated with Matrigel and treated with 
radiation alone or in combination with the inhibitors for 24 hours.  Cells were fixed and 
incubated with γ-H2AX or p-His H3 S10 antibodies overnight at 4oC followed by incubation 
with secondary conjugated antibodies. Nuclei were counterstained with Vectashield 
containing DAPI. Images were acquired using Zeiss LSM 710 confocal microscope and 
analysed using Velocity software (PerkinElmer).  γ-H2AX foci data are presented as box and 
whisker plots from 3 independent experiments unless otherwise stated and analysed using 
Mann Whitney U-test as they were not normally distributed.  
Flow cytometry, cell cycle distribution and proliferation and cell death 
For analysis of mitotic population, cells were treated and fixed with 70% ethanol and 
incubated with p-His H3 S10 antibody followed by γ-H2AX antibody and analysed using flow 
cytometry.  Combined annexin V and PI analysis was carried out according to 
manufacturer’s protocol (BD Biosciences).  Analysis of GSC markers was carried out using 
conjugated CD133 and CD15 (Miltenyi Biotech).  FACS was carried out using FACSAria 
Fusion following labelling with CD133/CD15-PE conjugated antibodies (Miltenyi Biotech).  
Live cells were gated and sorted populations were plated into 6 well plates in identical stem 
cell culture media for 3-7 days before harvesting.  Cell cycle distribution was determined 
following 40 minutes incubation with 10µM BrdU followed by flow cytometric analysis 
according to manufacturer’s protocol (BD Biosciences).  Data was analysed using FlowJo 
software (Tristar).  Analysis of caspase 3/7 activity was carried out using Caspase-Glo 3/7 kit 
(Promega). 
Cell proliferation was measured in 96 well plates with 200-400 cells seeded per well in 
replicates of 5.  Every 24-48 hours plates were fixed in 4% formaldehyde followed by DAPI 
staining.  Nuclei were counted using Operetta (PerkinElmer).  Cell doubling times were 
calculated from exponential growth curve fits using GraphPad Prism.       
Western blotting 
For immunoblotting whole cell lysates were prepared and processed in SDS buffer, blotted 
onto membranes and probed with primary antibodies (supplementary material and methods) 
overnight followed by appropriate secondary antibodies for 1-3 hours.  Bound antibodies 
were visualised using chemiluminescence (Thermo Scientific) and bands quantified using 
Image J.  
Statistical Analyses 
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All experiments were repeated 3 times unless otherwise stated and data points reported as 
mean +/- SEM. Statistical analysis and graphs were produced using Minitab 16 and 
Graphpad Prism 6.  Unpaired t-test or one sample t-test were used to generate p values. 
Word count: 918
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Results 
GSC populations are radioresistant  
We have previously characterised two primary GBM cell lines (E2 and G7) (27,37).  Using 
the same techniques three additional primary GBM cell lines (R10, R15 and R24) were 
expanded by culturing under selective media to enrich for or deplete the GSC population. 
We demonstrated that GSC enriched populations of E2, G7 (27,37), R10 and R15 cells 
generate orthotopic tumours in immunodeficient mice that recapitulate the human disease, 
whereas GSC depleted, tumour bulk populations do not (supplementary Figure S1). While 
the neural stem cell markers nestin, SOX2, CD133, Olig2 and CD15 were heterogeneously 
expressed between different GSC cultures, expression of these markers was consistently 
increased in GSCs compared to bulk populations (Figure 1A and 1B).  Clonogenic survival 
assays in E2 and G7 cell lines confirmed GSC cultures to be more radioresistant than paired 
bulk populations. Dose modifying factors calculated at 37% survival (DMF0.37) showed that 
E2 and G7 GSCs were more radioresistant than corresponding bulk populations by factors 
of 1.36 (p=0.001) and 1.44 (p<0.001) respectively (Figure 1C-E).  Radioresistance of GSC 
populations was confirmed by comparing surviving fraction at 4Gy (SF4Gy, supplementary 
Table 1).  These findings were consistent with the observation that E2 and G7 GSCs were 
refractory to cell death as measured by Annexin-V and propidium iodide staining following 
treatment with high radiation doses (15 and 30 Gy, Figure 1F, supplementary Figure S2). 
Caspase 3/7 activity assays supported the assertion that GSC populations are extremely 
resistant to radiation induced apoptotic cell death (Figure 1G). 
GSCs express high levels of DDR targets under basal conditions and activate CHK1 
rapidly following IR 
DDR targets have previously been shown to be upregulated and associated with GSC 
radioresistance (10,27,35).  We explored this further in our GSC and bulk culture models 
and observed an overall pattern of higher levels of total and phosphorylated CHK1 (S345) 
and ATR (S428) in GSCs compared to bulk populations in primary GBM cell lines (Figure 
2A).  Importantly this was not an artefact of culture conditions since CD133 or CD15 positive 
sorted cells exhibited significantly higher levels of phosphorylated CHK1 than negative 
sorted populations of E2, R24 and G7 cell lines cultured in the same conditions (Figure 2B).  
Higher levels of total CHK1 were also observed in R24 and G7 cells expressing the relevant 
stem cell marker. 
We next explored if differences in cell cycle distribution could account for the disparate 
CHK1 levels observed in GSC and bulk populations since CHK1 is typically expressed in S 
and G2 phases of proliferating cells. Analysis of BrdU incorporation indeed revealed 
significant differences in cell cycle profiles between these two populations (Figure 2C and 
supplementary Figure S3) with GSCs exhibiting a marked increase in the percentage of cells 
in S and G2 phases of the cell cycle.  Interestingly, the differences in cell cycle distribution 
had no significant impact on cell doubling times, which were similar in GSC and bulk 
populations in both E2 and G7 cell lines (supplementary Figure S3).  While these results 
might explain the observed increase in CHK1 levels in GSC they also indicate that enhanced 
radioresistance of GSCs is not a consequence of reduced proliferation rates. 
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Further interrogation of DDR markers revealed higher levels of PARP-1 and phosphorylated 
ATM (p-ATM, S1981) in the majority of the GSC populations (Figure 2A).  To confirm these 
findings in vivo we generated xenograft tumours from E2 and G7 GSC using an orthotopic 
mouse model.  Analysis of tumour sections revealed a heterogeneous pattern of p-ATM 
(S1981) and PARP-1 staining highlighting differential protein expression between different 
cell populations (Figure 2D).   PARP-1 staining in G7 tumours was abundant and 
homogeneous, consistent with previous reports proposing PARP-1 as a GBM marker (24). 
These findings were reproduced in a clinical GBM specimen, which exhibited marked p-ATM 
and PARP-1 expression in the majority of tumour cells (Figure 2D).  These data illustrate 
collective upregulation and/or activation of DDR targets in GSC populations under basal 
conditions in vitro and in a subpopulation of GBM cells in vivo. 
We next sought to investigate how differences in basal CHK1 levels between GSC and bulk 
populations affect the DDR.  Irradiation of E2 GSCs evoked more pronounced activation of 
CHK1 than in the corresponding bulk populations as demonstrated by a significantly greater 
increase in the phospho-CHK1 S345: total CHK1 ratio within 15 minutes that was maintained 
for at least 3 hours (Figure 2E and 2F).  Reduced CHK1 activation in E2 bulk cells occurred 
despite similar levels of DNA damage induction (γ-H2AX).  While the relative extent of 
radiation induced CHK1 activation was similar in bulk and GSC populations of G7 cells 
(supplementary Figure S4), absolute levels of CHK1 and p-CHK1 were significantly higher in 
G7 GSC than in paired bulk cells both under basal conditions and following irradiation.  
CHK2 activation (T68 phosphorylation) was similar in E2 GSC and bulk populations although 
differences were observed between G7 bulk and GSC populations (Figure 2E and 
supplementary Figure S4).  We explored the possibility that enhanced activation of CHK1 in 
GSC could be caused by ‘priming’ of the MRN (MRE11, RAD50, NBS1) DNA damage 
sensor complex under basal conditions.  No differences in total or phosphorylated MRE11 
and NBS1 between GSC and bulk populations were observed under basal conditions or 
following irradiation, but modest upregulation of RAD50 was observed in E2 and G7 GSCs 
following irradiation (Figure 2E, supplementary Figure S4). The possibility that CHK1 
activation was delayed (rather than reduced) in bulk cells was excluded by demonstrating 
that S296 phosphorylation of CHK1 was attenuated in E2 and absent in G7 bulk cells but 
maintained in both GSC cultures at 6, 12 and 24 hours after irradiation (Figure 2G).  While 
some variation in the kinetics of CHK1 activation in GSCs was observed between different 
experiments, which could be due to the use of different batches of frozen primary patient 
derived cells, both phosphorylated and total CHK1 levels were consistently higher in GSCs 
than bulk cells and were reproducibly augmented at all time points following radiation. 
Finally, the enhanced CHK1 activation in GSC was not only a radiation specific 
phenomenon: E2 and G7 GSC also exhibited markedly enhanced activation of CHK1 (S345 
and S296 phosphorylation) in response to UV, hydroxyurea or aphidicolin treatments despite 
levels of γ-H2AX induction that were comparable to bulk populations (Figure 2H, 
supplementary Figure S4). 
Rapid induction of CHK1 in GSCs is associated with enhanced G2/M cell cycle 
checkpoint activation 
We next investigated the impact of enhanced CHK1 activation on cell cycle checkpoint 
responses of GSCs.  Both E2 and G7 cell lines were refractory to radiation induced G1/S 
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checkpoint activation, consistent with frequent deregulation of p53 signalling pathways in 
GBM (38) (supplementary Figure S5).  However, analysis of the G2/M checkpoint by flow 
cytometric quantification of mitotic cells identified by S10 phosphorylation on histone H3 (p-
His H3) revealed that GSC activated G2 arrest significantly more efficiently than paired bulk 
populations, requiring less time to reduce the mitotic cell population by 50% following IR 
treatment (Figure 3A, supplementary Figure S6).  Consistent with this, E2 CD133+ sorted 
cells activated G2 arrest more rapidly and completely than CD133- cells cultured in the same 
conditions (supplementary Figure S7).  Intriguingly, E2 bulk cells failed to fully activate the 
G2/M checkpoint at any time point (Figure 3C).  Further dose response studies revealed that 
depletion of mitotic cell fraction by 75% occurred after significantly lower radiation doses in 
E2 and G7 GSC compared to bulk populations (Figure 3B, supplementary Figure S6) and 
that E2 and G7 bulk cells were released from the G2/M checkpoint earlier than GSC (Figure 
3C).  Taken together our results indicate that increased and/or more rapid activation of 
CHK1 might be responsible for the enhanced radioresistance of GSC and that the relative 
radiosensitivity of tumour bulk cells (Figure 1) might be at least partly explained by these 
cells entering mitosis carrying unrepaired DNA damage (see also Figure 6). 
Radiosensitising effects of CHK1 inhibition are more pronounced in GBM bulk cells 
than GSCs 
Reasoning that radioresistance of GSCs might be driven by enhanced CHK1 mediated 
activation of the G2/M checkpoint, we hypothesised that inhibition of CHK1 would abrogate 
the G2/M checkpoint and increase radiosensitivity. To investigated this we utilised SCH 
900776 (SCH) a well characterised CHK1 specific inhibitor which had no significant effect on 
CHK2 activity as highlighted by unaltered phosphorylation of T68 (Figure 4A-C) (39,40).  As 
expected, SCH treatment alone inhibited CHK1 S296 autophosphorylation in a dose 
dependent manner and induced CHK1 S345 phosphorylation through CHK1 dependent 
inhibition of the PP2A phosphatase feedback loop (41) (Figure 4A and 4C, supplementary 
Figure S8).  Treatment of E2 GSCs with SCH resulted in enhanced induction of CHK1 S345 
phosphorylation by UV or IR along with increased γ-H2AX levels reflecting increased DNA 
damaging signalling in response to CHK1 inhibition (Figure 4A-C and supplementary Figure 
S8).  Interestingly, induction of CHK2 T68 phosphorylation was also observed following 
combined treatment with SCH plus IR suggesting compensatory activation of CHK2 
following CHK1 inhibition (Figure 4C) (42).  In addition SCH treatment alone generated a γ-
H2AX signal highlighting a basal function of CHK1 in maintaining genomic stability (43).  
Additional biomarkers of CHK1 inhibition included downregulation of phosphorylated Wee1 
(S642) and CDC25C (T48) whilst upregulation of CDC25A was observed following SCH 
treatment alone and augmented in combination with radiation, consistent with enhanced cell 
cycle progression despite the presence of damaged DNA (Figure 4B and 4C, supplementary 
Figure S8). 
Since our earlier results showed that GSCs rapidly activate the G2/M cell cycle checkpoint in 
response to IR (Figure 3), we hypothesised that CHK1 inhibition would abolish this effect 
and thus overcome the radioresistant GSC phenotype.  Indeed, SCH treatment abrogated 
radiation induced G2 arrest in E2 and significantly attenuated it in G7 GSCs, while SCH 
treatment in the absence of radiation was sufficient to drive E2 and G7 GSCs into mitosis 
(Figure 4D).  Importantly, clonogenic survival assays confirmed significant radiosensitisation 
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of E2 and G7 GSC by CHK1 inhibition as illustrated by sensitisation enhancement ratios at 
37% survival (SER0.37) of 1.9 and significant reductions in surviving fractions at 4Gy (SF4Gy) 
in both cell lines (Figure 4E and 4F).  Despite the limited ability of bulk populations to 
phosphorylate CHK1 and induce G2/M checkpoint activation in response to radiation, a 
similar or greater magnitude of radiosensitisation (SER0.37=2.3-2.4) was observed in bulk 
populations treated with SCH.  This unexpected observation was confirmed using an 
alternative CHK1 inhibitor CHIR-124 (44) (supplementary Figure S9).  While these data 
support the assertion that CHK1 inhibition has therapeutic potential in GBM, the observation 
that overexpression and constitutive activation of CHK1 in GSCs was not associated with 
increased radiosensitisation by CHK1 inhibitors indicates that additional mechanisms could 
be responsible for limiting the radiosensitisation effects of CHK1 inhibition in the GSC 
population. 
Inhibition of CHK1 radiosensitises GSC through a mechanism involving mitotic 
catastrophe 
Our subsequent studies were aimed at investigating the mechanisms responsible for (i) GSC 
radiosensitisation by CHK1 inhibition and (ii) enhanced radiosensitisation of bulk cells.  Initial 
analysis of DNA damage in E2 GSCs using flow cytometry highlighted a significant increase 
in the γ-H2AX positive cell population following combined SCH and IR treatment compared 
to individual treatments alone (Figure 5A and 5B).  Interestingly, SCH treatment alone 
induced a γ-H2AX response, confirming our earlier observations (Figure 4A-C).  Since this 
signal was observed predominantly in S-phase cells, we inferred that CHK1 inhibition 
exacerbates replication stress in GSCs.  Since SCH treatment also inhibited the G2/M 
checkpoint (Figure 4D) we investigated whether treated GSCs would enter mitosis with 
damaged DNA. Indeed, following SCH treatment we observed a distinct population of mitotic 
cells with high γ-H2AX signal that was significantly increased after combined treatment with 
SCH and IR (Figure 5C and 5D).  Immunofluorescence analysis confirmed these results, 
demonstrating a distinct mitotic cell population with intense, pan-nuclear γ-H2AX staining 
(middle row, Figure 5E).  This is likely to represent cells in the initial stages of mitotic 
catastrophe, which was clearly visible in a separate population of mitotic cells characterised 
by loss of membrane integrity and fragmented morphology (bottom row).  Both populations 
were augmented in GSCs following combined treatment with SCH and IR relative to either 
treatment alone.  In addition, we evaluated the consequence of mitotic division in cells with 
damaged DNA and found a significant increase in the percentage of GSCs harbouring one 
or more micronucleus following the combined treatment (Figure 5F).  Taken together, our 
data demonstrate that CHK1 inhibition sensitises GSC to IR by preventing G2/M checkpoint 
activation, allowing mitotic entry of cells bearing damaged DNA resulting in mitotic 
catastrophe and genomic instability. 
Limited radiosensitisation of GSCs by CHK1 inhibition is explained by enhanced DNA 
repair 
We next sought to identify the mechanism responsible for limiting the radiosensitising effects 
of CHK1 inhibition in GSCs by comparing effects of IR plus SCH with those observed in 
paired bulk cell populations in which SCH had shown more pronounced radiosensitising 
effects (Figure 4E and 4F).  Analysis of G7 cells revealed a significant increase in both total 
and mitosis specific γ-H2AX positive cells in the bulk population compared to GSCs following 
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treatment with SCH alone or in combination with radiation (Figure 6A and 6B).  Similarly, 
significantly more mitotic catastrophe events were observed in bulk populations than in 
GSCs (Figure 6C).  Although E2 GSCs treated with SCH and IR showed an increased total 
number of γ-H2AX positive cells compared to the paired bulk cells, this did not translate into 
increased mitotic damage or mitotic catastrophe (supplementary Figure S10).   Indeed, even 
when SCH and IR had increased the DNA damage burden in E2 GSCs, the majority of these 
cells proceeded to mitosis having repaired this damage, as indicated by a significant 
reduction in γ-H2AX positive mitotic cells and fewer cells exhibiting mitotic catastrophe 
compared to the paired bulks population (Supplementary Figure S10).  Thus, enhanced DNA 
repair appears to compensate for the significant increase in DNA damage observed in GSCs 
treated with radiation and CHK1 inhibitor.  Consistent with this, analysis of micronuclei, 
which are formed as a direct consequence of mitotic division in cells with unrepaired DNA 
DSBs, revealed that GSCs exhibit significantly enhanced DNA repair capacity when 
compared with bulk cells in both E2 and G7 cell lines (Figure 6D and supplementary Figure 
S10). This theory is also corroborated by the observation that a significantly higher 
percentage of bulk cells than GSCs harbour micronuclei under basal conditions.  To 
substantiate this hypothesis, detailed analysis of DNA DSB repair was conducted by 
quantification of γ-H2AX foci in CENPF positive (G2/M) and negative (G1) cells 24 hours 
after high dose radiation (10 Gy). This clearly showed increased repair proficiency of GSCs 
compared to bulk population (Figure 6E and 6F), supporting our earlier hypothesis that 
enhanced DNA repair is responsible for the attenuated radiosensitising effects of CHK1 
inhibition in E2 and G7 GSCs.  
Optimum radiosensitisation of GSCs through parallel inhibition of DNA damage 
response pathways 
In order to identify the optimum targets for GSC radiosensitisation we evaluated small 
molecule inhibitors of additional DDR proteins that were up-regulated in GSCs (Figure 2A).  
DNA repair was targeted using the PARP inhibitor olaparib, cell cycle checkpoints were 
inhibited using the ATR inhibitor VE821 and combined targeting of cell cycle checkpoints 
and DNA repair was evaluated using the ATM inhibitor KU55933.  Results in E2 cells 
showed that ATR inhibition sensitised GSC and bulk populations equally although there was 
a trend towards increased radiosensitisation of bulk cells (Figure 7A and 7B).  SER0.37 
values for ATR and CHK1 inhibition were comparable.  In contrast, inhibition of PARP or 
ATM revealed a trend towards increased radiosensitisation of GSCs. The ATM inhibitor 
KU55933 proved to be the most potent radiosensitiser of GSC (SER0.37=2.60, Figure 7B). 
To understand the reasons for the different magnitudes of GSC radiosensitisation by the 
DDR inhibitors we investigated their effects on cell cycle checkpoints and DNA repair.  
Whereas inhibition of either ATR or CHK1 completely ablated radiation induced G2/M 
checkpoint activation (Figure 7C), inhibition of ATM had only a partial effect. In contrast, 
ATM inhibition significantly impaired repair of radiation induced DSBs as demonstrated by a 
significant increase in the number of unresolved γ-H2AX foci 24 hours post-irradiation 
(Figure 7D).  A similar effect on DNA repair was observed following PARP inhibition.  
Considering that ATM inhibition was associated with the greatest radiosensitisation of GSCs 
we hypothesised that dual inhibition of cell cycle checkpoint activation and DNA repair might 
provide optimum radiopotentiation.  This was investigated by concomitant inhibition of DNA 
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repair and cell cycle checkpoint function by combined treatment with inhibitors of PARP and 
ATR. As predicted, the radiosensitising effect of this combination in GSCs exceeded that of 
any of the inhibitors individually (SER0.37=3.20, Figure 7E) and was significantly greater than 
that observed in the paired bulk cells.  This is likely to be due to increased unrepaired DSBs 
since combined inhibition of ATR and PARP was shown to be associated with a significant 
increase in γ-H2AX foci in GSCs compared to the bulk population (supplementary Figure 
S11).  To support the clinical relevance of this result we performed neurosphere formation 
assays using E2 GSCs and confirmed that dual inhibition of ATR and PARP achieved 
maximum potentiation of the inhibitory effects of radiation on neurosphere formation (Figure 
7F).  Taken together our results show that optimal radiosensitisation of GSCs is achieved 
through parallel inhibition of DDR pathways. 
Word count: 2845
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Discussion 
GBM are heterogeneous tumours that are thought to be dependent on a cellular hierarchy 
that includes a privileged GSC subpopulation resistant to conventional therapy and capable 
of tumour propagation and growth.  Uncertainty over the ideal model(s) in which to study 
radiation responses of the GSC population may account for the disparities in the findings of 
the various published studies (10,25,26).  In keeping with our previous studies we generated 
paired cultures of primary, patient derived GBM cell lines (10,35) in which the GSC 
population was either enriched or depleted (27).  While the use of sorted cell populations 
based on a specific stem cell marker such as CD133 has been questioned because both 
CD133+ and CD133- cells have been capable of generating tumours in vivo (45), we utilised 
this technique to validate observations made in our enriched populations and to exclude the 
potential confounding effects of different cell culture conditions.  The GSC “signature” is 
likely to be complex, modulated by the cellular microenvironment and governed by multiple 
parameters including epigenetic and genetic aberrations which impact upon the expression 
of key regulatory proteins.  In keeping with this interpretation, a recent publication highlights 
four core neurodevelopment transcription factors that are crucial to GSC maintenance and 
tumourigenicity (46). 
Our study shows that GSCs are more radioresistant than paired bulk populations and exhibit 
higher expression of total and activated DDR targets under basal conditions.  The reason for 
this is unclear; we speculate that it may reflect an endogenous response of neural stem cells 
to DNA damage which is subsequently maintained as part of mutagenic selection and the 
malignant phenotype.  In addition, genetic differences between GSCs and bulk cells may 
affect cellular biochemistry, possibly accounting for lower proteasomal activity in GSCs 
contributing to higher levels of DDR targets (47).  More recently increased levels of reactive 
oxygen species have been proposed as a mechanism responsible for upregulated PARP-1 
in GSCs (35). 
One surprising observation was the apparent lack of CHK1 activation in bulk cells exposed 
to IR.  This observation and the slower DNA repair kinetics of these cells might explain why 
they are significantly more radiosensitive than the GSC population. Whilst our results 
support this, it should be emphasised that the bulk cells remain relatively radioresistant, 
suggesting that alternative pathways might compensate for the lack of CHK1 activation and 
attenuated DDR.  Indeed, non-canonical DDR pathways including NOTCH, TGFβ and 
receptor tyrosine kinase signalling have all been associated with GBM radioresistance and 
may be activated in these cells (reviewed in (48).  Alternatively, bulk cells may rely on DNA 
damage tolerance (DDT) mechanisms which utilise translesion synthesis polymerases to 
bypass lesions for repair at later time points (49).  This provides a mechanism to tolerate 
DNA damage allowing cells to continue replicating and might explain the survival of bulk 
cells following IR despite the lack of checkpoint activation and early checkpoint release. 
The MRN complex is a crucial DNA damage sensor that is recruited to and participates in 
DNA DSB repair.  Although our results show no significant differences in the levels of total 
and phosphorylated components of the MRN complex between GSC and bulk populations, 
the rate at which the complex is recruited to damaged site and catalytic activity of specific 
components might conceivably be greater in GSCs thus contributing to their enhanced 
radioresistance. 
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Our study shows that multiple DDR targets including ATR, ATM, CHK1 and PARP-1 are 
upregulated in GSCs compared to the bulk population, and that some are also preferentially 
activated.  Although some of these targets have overlapping functions, individually they have 
distinct roles which suggest that multiple DDR pathways contribute to GSC radioresistance.  
Our studies showed that both GSC and bulk populations were radiosensitised by CHK1 or 
ATR inhibition despite higher expression and activity of these proteins in GSCs. This led us 
to propose that alternative DDR pathways might mitigate the radiosensitising effects of 
CHK1 or ATR inhibition in the GSC populations. In support of this explanation, inhibition of 
ATM, with its dual functions in DNA repair and cell cycle checkpoint activation, yielded the 
most potent single agent radiosensitisation of GSCs.  Importantly we confirmed this 
hypothesis by demonstrating that combined inhibition of ATR and PARP generated 
maximum radiosensitisation, and that this effect was of significantly greater magnitude in 
GSCs than in bulk populations. Inhibition of PARP resulted in a significant increase in DNA 
DSBs, which were likely to have been generated during S-phase from unrepaired DNA 
SSBs. In the context of ATR inhibition these cells were unable to activate the G2/M cell cycle 
checkpoint and thus entered mitosis carrying high levels of unresolved DSBs.  We therefore 
propose that GSC radioresistance is driven by both enhanced cell cycle checkpoint 
activation and DNA repair, and that optimal radiosensitisation can only be achieved by dual 
inhibition of both pathways. 
Our data strongly support further pre-clinical evaluation of ATR and PARP inhibitors in 
combination with IR as a potential treatment for GBM.  This is an entirely novel approach 
that to our knowledge has not been investigated in any cancer models.  Clearly there will be 
concerns over the potential in vivo toxicity of this combination treatment modality: ATR is 
essential for tissue homeostasis, highlighted by embryonic lethality of ATR knockout mice, 
whereas PARP1 knockout in mice is less deleterious.  However, clinical experience with 
PARP inhibitors has been extremely promising; it is tolerated well as a single agent and 
clinical studies in combination with radiation are progressing.  To our knowledge only one 
clinical study is currently recruiting patients to explore ATR inhibition as a radiosensitising 
strategy in advanced solid tumours (www.clinicaltrials.gov).  However, a pre-clinical study 
using the ATR inhibitor VE822 has demonstrated radiosensitisation of pancreatic tumours in 
mice with no apparent in vivo toxicity (50).  The high proliferation indices of most GBM is 
predicted to render them more sensitive to the combination of radiotherapy, PARP inhibition 
(33) and ATR inhibition, and the GSC specific radiosensitisation mechanisms outlined in this 
paper are associated exclusively with S, G2 and M phases of the cell cycle.  Since normal 
brain tissues are comprised almost entirely of non-replicating, post-mitotic cells with intact 
G1/S checkpoint and DNA repair pathways, we predict that the radiosensitising effects of the 
proposed combination will be exerted exclusively upon GBM tumour cells, and will have 
particular impact on the radioresistant GSC population.     
In summary, our study provides the first detailed examination of DDR responses in GSCs 
and has important implications for the management of GBM.  Our results support the notion 
that GSCs are profoundly radioresistant and identify a novel drug combination strategy 
targeting both cell cycle checkpoint and DNA repair functions that has potential to overcome 
this.  Future studies will focus on in vivo characterisation of this strategy and will identify 
optimal radiation/drug combination scheduling to take forward to phase I clinical trials in 
GBM patients. 
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Figure legends 
Figure 1.  GSCs are radioresistant with defective DDR 
(A)  Enrichment of stem cell markers SOX2, Nestin, CD133 and Olig2 under GSC culture 
conditions compared to paired bulk populations of primary patient derived GBM cell lines.  
(B) Flow cytometry plots and summary showing relative expression of CD133 and CD15 in 
E2 and G7 GSC and bulk populations. (C-D)  Clonogenic survival assays showing E2 and 
G7 GSCs are more radioresistant than paired bulk populations. (E) Calculation of dose 
modifying factor (DMF) at 37% survival comparing E2 and G7 GSC vs bulk populations and 
p values associated with comparisons of DMF.  (F) Plots summarising combined annexin V 
and PI staining or (G) fold induction in caspase 3/7 activity at 48 hours in E2 and G7 GSC 
and bulk populations following treatment with 15 or 30 Gy ionising radiation. Error bars show 
mean ± SEM from n=3 independent experiments, * p<0.05, NS=non-significant. 
Figure 2. GSCs have upregulated DDR proteins under basal condition and active 
CHK1 rapidly following IR 
(A) Analysis of multiple DDR proteins under basal conditions in GSC or bulk populations in a 
panel of primary patient derived GBM cell lines.  Loading control as shown in Figure 1A.  (B) 
Analysis of total and phosphorylated CHK1 in CD133 or CD15 sorted cell populations.  Flow 
cytometry plots show post-sort analysis of G7 cells sorted by CD15 expression.  (C) Cell 
cycle distribution and profiles of E2 GSC and bulk populations.  (D) Immunohistochemistry 
analysis of orthotopic tumour sections generated from E2 and G7 orthotopic xenografts and 
a GBM patient specimen showing PARP1 and p-ATM staining. (E) Western blots showing 
rapid activation of DNA damage response markers at early time points in E2 GSC compared 
to bulk populations following 5Gy IR.   (F) Fold induction in CHK1 activation relative to 
untreated cells following quantification of p-CHK1(S345):CHK1 ratios from immunoblots after 
radiation.  Error bars show mean + SEM from three independent experiments.  (G) 24 hour 
time course highlighting CHK1 and phosporylated CHK1 levels in E2 and G7 paired GSC 
and bulk populations following 5Gy IR.  (H) Response of E2 bulk and GSC populations to 
various activators of CHK1: IR=5Gy, 1hr; UV=10JM-2, 1hr; HU=10mM, 3hr; 
Aphidicolin=1mM, 3hr, (* longer exposure). 
Figure 3.  Rapid activation of G2/M cell cycle checkpoint in GSCs following IR 
Summary of flow cytometry data analysing mitotic p-His H3 S10 cell population to measure 
G2/M cell cycle checkpoint in paired E2 and G7 GSC and bulk populations. (A) 3 hour time 
course following 5Gy IR treatment showing a rapid activation of G2/M checkpoint in GSCs 
as measured by the time required to reduce mitotic population by 50%.  (B) IR dose 
response showing E2 and G7 GSC populations require significantly lower dose of radiation 
compared to the bulk cells to activate G2/M checkpoint by 75% relative to unirradiated cells. 
(C) 12 hour IR time course showing E2 and G7 bulk cells exit the G2/M checkpoint 
significantly quicker than the paired GSC population as measured by the time required for 
mitotic cell population to return to baseline levels.  Plots show mean ± SEM, n≥3 
independent experiments. 
Figure 4. GSCs are radiosensitised by the CHK1 inhibitor SCH900776 (SCH) 
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(A) Inhibition of CHK1 in E2 GSCs following 1 hr pre-treatment with various concentrations 
of SCH followed by 120Jcm-2 UV for 1hr.  (B)  Time course showing abrogation of IR induced 
CHK1 activation by pre-treatment of E2 GSCs with 3µM of SCH for 1hr (* denotes longer 
exposure). (C) Analysis of multiple biomarkers of CHK1 inhibition at 24 hours in E2 GSCs 
treated with various concentrations of SCH for 1hr followed by 5Gy IR.  (D)  Plots 
summarising flow cytometry data showing inhibition of IR induced G2/M checkpoint 
activation in E2 and G7 GSCs treated with 3µM SCH for 1hr followed by 5Gy IR, (mean ± 
SEM from n≥3 independent experiments, *p<0.05, **p<0.01,***p<0.001 relative to IR alone. 
(E)  Clonogenic survival curves showing radiosensitisation of E2 and G7 GSC and bulk 
populations following 3µM of SCH treatment. (F) Summary of clonogenic data showing SER 
of GSC and bulk populations at 37% survival and SF at 4Gy in the presence or absence of 
SCH. * denotes p<0.05 based on the 95% confidence intervals between SER of GSCs and 
bulk population or SF of GSC or bulk  populations plus or minus SCH treatment. NS=Non 
significant. 
Figure 5. Inhibition of CHK1 increases DNA damage, induces mitotic catastrophe and 
leads to genomic instability in irradiated GSC 
(A) Representative flow cytometry plots showing the total percentage of γ-H2AX positive 
cells in E2 GSC 24 hours after 3µM SCH treatment for 1 hr followed by 5Gy IR.  (B) Bar 
chart summarising the percentage of total γ-H2AX positive cells at 24 hours following 
treatment of E2 GSCs with various concentrations of SCH +/- 5 Gy, error bars show mean + 
SEM, n≥3 independent experiments, *p<0.05.  (C) Representative histogram plots from flow 
cytometry data showing the percentage of mitotic cells with high γ-H2AX at 24 hours 
following treatment with 3µM SCH and 5Gy IR.  (D) Summary of flow cytometry data 
showing percentage of mitotic cells with high γ-H2AX at 24 hours following treatment of E2 
GSC with various concentrations of SCH, error bars show  mean + SEM, n≥3 independent 
experiments, *p<0.05, **p<0.01. (E) Representative immunofluorescence images showing p-
His H3 positive mitotic cells (green) with no/low γ-H2AX  (red, top panel) or high γ-H2AX 
(middle panel).   Image of cell undergoing mitotic catastrophe as marked by nuclear blebbing 
and high γ-H2AX (bottom panel).  DAPI nuclear stain in blue.  Bar charts summarising 
immunofluorescence data from analysis of ∼75 mitotic cells.  (F) Representative image and 
summary of the percentage of E2 GSCs with micronuclei (arrows) 24 hours following 
treatment with 3µM SCH +/- 5 Gy, error bars show mean + SEM from scoring ∼ 500 nuclei, 
*p<0.05, **p<0.01). 
Figure 6. GSC show enhanced DNA repair capacity following irradiation and/or CHK1 
inhibition 
Summary of flow cytometry data showing the percentage of (A) γ-H2AX positive cells, (B) 
mitotic cells with high γ-H2AX and (C) mitotic catastrophe (arrows) in paired G7 bulk and 
GSC populations at 24 hours following treatment with 3µM SCH and/or 5Gy IR, error bars 
show mean + SEM, n≥3 independent experiments, **p<0.01, **p<0.001. (D)  Bar chart 
summary of the percentage of G7 bulk and GSC with micronuclei 24 hours following the 
indicated treatment combinations, error bars show mean + SEM from scoring ∼ 600 nuclei, 
***p<0.001.  (E) Representative immunofluorescence images of E2 GSC and bulk 
populations at 24 hours following 10Gy IR, γ-H2AX foci (green), CENPF (red) and DAPI 
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(blue). (F)   Plots showing median  γ-H2AX foci  per nucleus in E2 bulk and GSC CENPF 
positive or negative cells populations from scoring  a minimum 65 (CENPF positive) or 300  
(CENPF negative) nuclei, *p<0.05, **p<0.01. 
Figure 7. Enhanced radiosensitisation of GSCs by parallel inhibition of DNA repair 
and cell cycle checkpoint pathways 
(A-B) Clonogenic survival curves in E2 GSC and bulk populations following treatment with 
multiple DDRi in combination with radiation. (B) Summary of SER at 37% survival in paired 
populations with 95% confidence intervals, *p<0.05 and NS=non-significant between GSC 
and bulk population. CHK1i data as shown previously in Figure 4E & 4F. (C) Inhibition of 
radiation induced G2/M checkpoint activation in E2 GSCs following 5Gy IR treatment in the 
presence of various DDRi, significance relative to DMSO treatment (IR alone); *p<0.05, 
**p<0.01, ***p<0.001.  (D) Plots showing median number of γ-H2AX foci in CENPF positive 
cells at 24 hours following treatment with IR in combination with DDRi, minimum of 65 nuclei 
scored; ***p<0.001. (E) Clonogenic survival curves in E2 cells showing significant 
radiosensitisation of GSC over the bulk population as shown by the SER following combined 
treatment with ATR+PARP inhibitors in combination with radiation.  ATMi data as shown in 
part A and B. (F) Neurosphere formation assay showing maximum reduction in the number 
of neurospheres at 4 weeks following ATR+PARP1 inhibition in combination with radiation;  
**p<0.01, ***p<0.001.   
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Supplementary Table 1. 
Analysis of clonogenics survival curves from Figure 1C and 1D showing colony surviving 
fractions at 4Gy in E2 and G7 bulk and GSC populations with 95% confidence interval and 
p-values based on t-test of means. 
Supplementary Table 1 
Supplementary Figure S1.   Generation of orthotopic tumours from R10 and R15 GSCs 
Immunohistochemistry images of  tumour sections  stained with Hematoxylin and eosin 
(H&E) showing tumour cell morphology and Ki67 showing proliferating tumour cells 
Supplementary Figure S1 
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Supplementary Figure S2. GSCs are more resistant to IR induced cell 
death than bulk populations 
(A-B) Flow cytometry plots showing percentage of annexin V and PI staining 
in G7 and E2 GSC and bulk populations following  48 hours treatment with 15 
or 30 Gy IR. 
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Supplementary Figure S3.  Cell cycle profile and proliferation rates of GSC and bulk population 
(A) Representative BrdU cell cycle profiles and summary of cell cycle distribution in untreated G7 GSC 
and bulk population.  (B) Cell growth curves with exponential growth fit measuring cell doubling rates in 
GSC and the bulk populations in E2 and G7 cell lines. 
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Supplementary Figure S4.  Enhanced activation of CHK1 in GSCs 
(A) Western blots showing activation of DNA damage response markers at early time points in G7 bulk and 
GSC population following 5Gy IR.  (B) Fold induction in CHK1 activation at various time points following 
quantification of p-CHK1(S345)/CHK1 immunoblots  in irradiated  G7 bulk and GSCs.  Untreated conditions 
normalised to 1, error bars show mean + SD from three independent experiments,   (C) Response of G7 bulk 
and paired GSC populations to various activators of CHK1: IR=5Gy, 1hr; UV=10JM-2, 1hr; HU=10mM, 3hr; 
Aphidicolin=1mM, 3hr, (* longer exposure). 
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Supplementary Figure S5.  Absence of G1 cell cycle checkpoint in irradiated GBM cell lines 
Cell cycle distribution in G7 and E2 paired GSC and bulk population following 5Gy IR treatment at 
the time points indicated. 
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Supplementary Figure S6.  Analysis of G2/M cell cycle checkpoint 
Representative flow cytometry plots showing  the percentage of mitotic p-His H3 S10 cells in E2 GSCs and bulk 
population following (A) 5Gy IR (time course) and (B) IR dose response (3 hours).  Graphs show the actual (top) 
and normalised (bottom) p-His H3 S10 levels.  
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Supplementary Figure S7 
Supplementary Figure S7.   Rapid activation of G2/M cell cycle checkpoint in E2 CD133+ cells 
CD133+ and CD133- sorted cells were irradiated with 5Gy IR followed by flow cytometry analysis of 
mitotic p-His H3 S10 population at the time point indicated.  (A) Normalised data relative to untreated 
(B) representative flow cytometry profiles. 
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Supplementary Figure S8.  Treatment of G7 GSCs with the CHK1 inhibitor SCH 900776 (SCH) 
(A)  Time course showing abrogation of IR induced CHK1 activation by pre-treatment of G7 GSCs with 3µM of 
SCH for 1hr (* denotes longer exposure). (B) Analysis of multiple biomarkers of CHK1 inhibition at 24 hours in G7 
GSCs treated with various concentrations of SCH for 1hr followed by 5Gy IR. 
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Supplementary Figure S9.  Radiosensitisation of E2 and G7 cells with the CHK1 inhibitor 
CHIR 124 (CHIR)  
(A) Dose response of CHK1 inhibition in E2 GSCs following 1 hr pre-treatment with CHIR  
followed by 120Jcm-2 UV for 1hr.  (B) Plot summarising flow cytometry data showing inhibition of 
IR induced G2/M checkpoint activation in E2 and G7 GSCs treated with 0.3µM CHIR for 1hr 
followed by 5Gy IR, mean ± SEM from n≥3 experiments, **p<0.01,***p<0.001 relative to IR alone. 
(C-D)  Clonogenic survival curves showing radiosensitisation of E2 and G7 GSCs and bulk 
populations following 0.3µM of CHIR treatment.  
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Supplementary Figure S10.  Enhanced DNA repair attenuates radiosensitisation of E2 GSCs to CHK1 
inhibitor (SCH) 
(A)  Representative flow cytometry profile of E2 bulk cells showing percentage of γ-H2AX positive cells following 
treatment with IR and/or CHK1 inhibitor (SCH) for 24 hours.  Corresponding plots in E2 GSCs is shown in Figure 5A.  
(B) Summary of γ-H2AX data in paired bulk and stem populations, error bars show mean + SEM from 3 independent 
experiments, *p<0.05.  (C) Percentage of cells with mitotic γ-H2AX, (D) mitotic catastrophe and (E) percentage of 
cells with micronuclei following treatment of GSC and bulk populations with IR and SCH, mean + SEM shown from 
three independent experiments, *p<0.05, **p<0.01,***p<0.001. 
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Supplementary Figure S11.   Increase in γ-H2AX foci in GSCs compared to 
bulk population following combined ATR and PARP inhibition  
Plot showing median γ-H2AX foci per nucleus in E2 bulk and GSCs following 
combined ATR and PARP1 inhibition at 48 hours. 
Supplementary materials and methods 
Maintenance of cell lines and orthotopic tumours generation 
Each GBM cell line was cultured in pairs either on Matrigel TM (Life Technology) coated 
flasks in AdvDMEM F12 medium (Gibco) supplemented with 1% B27 (Invitrogen), 0.5% N2 
(Invitrogen), 4µg/ml heparin, 20ng/ml bFG, 20ng/ml EGF (Sigma), and 1% L-Glutamine to 
maintain the GSC population or in MEM (Gibco) supplemented with 10% FBS Sigma, 1% L-
glutamine and 1% sodium pyruvate to deplete the GSCs and generate a differentiated 
tumour bulk population.  All cell cultures were maintained at 370C, 5% CO2.  Cell lines were 
utilised between 6-15 passages and then discarded.   
E2 GSC produced highly infiltrative tumours that resemble gliomatosis cerebri and tumour 
burden was significantly greater than those generated with the bulk cells.  G7 GSC tumours 
recapitulated key histological features of GBM and demonstrated an invasive phenotype 
whereas tumour from the paired bulk population produced well-demarcated, non-invasive 
tumours. 
Immunohistochemistry 
Immunohistochemistry was performed on 4µm sections cut from paraffin embedded 
samples. Heat-mediated antigen retrieval was conducted using a pressure cooker in a 
microwave with sections submersed in either 10mM sodium citrate target retrieval solution 
pH6 (Dako, S236984) for PARP1 staining, or pH9 (Dako, S2367) for pATM staining.  After 
blocking endogenous peroxidase (Dako, K400611-2), sections were washed in TBS-T, and 
PARP1 (Santa Cruz, sc8007) or pATM (S1981) (Abcam, ab81292) primary antibody was 
applied at an optimised dilution (1/600 PARP1, 1/200 pATM).  Sections were incubated in 
primary antibodies overnight in a humidified chamber.  The following day, sections were 
washed in TBS-T and secondary antibodies applied for 45mins at room temperature (Dako, 
K400611-2).  Staining was visualised by application of 3, 3’-diaminobenzidine 
tetrahydrochloride (Dako, K400611-2). 
Neurosphere assay 
For neurosphere assay 10 GSCs were seeded into each well of a 96 well plate in 100µL 
medium containing the drug or relative DMSO control for 1 hour followed by mock or 2Gy 
irradiation.  48 hours later a further 150 µL of fresh media was added per well. Neurospheres 
were manually counted under 5x magnification after 3 or 4 weeks for G7 and E2 GSC 
respectively.  
Immunofluorescence 
Cells were fixed in 4% formaldehyde/PBS and permeabilised, blocked with 5% FCS, 0.5% 
BSA in 0.1% Triton-PBS and incubated with γ-H2AX (Millipore, 1:100) and CENPF (Abcam, 
1:250) or p-His H3 S10 (Cell signalling, 1:100) antibodies overnight at 4oC followed by 
incubation with appropriate Alexa Fluor 568 or 488 secondary antibodies (Invitrogen). Nuclei 
were counterstained with Vectashield containing DAPI (Vector laboratories). 30 Z-stack 
images were acquired under each condition at 63x magnification using the Zeiss LSM 710 
confocal microscope analysed using Velocity software (PerkinElmer).  CENPF staining was 
determined by the operator and pan nuclear γ-H2AX staining was excluded from the 
analysis.  The number of nuclei analysed for each condition ranged from 65 to 307 (CENPF 
positive) and 300 to 460 (CENPF negative). 
Cell proliferation 
200-400 cells were seeded in 96 well plates in replicates of 5.  Every 24-48 hours plates 
were fixed in 4% formaldehyde followed by DAPI staining.  Nuclei were counted using 
Operetta (PerkinElmer).  Cell doubling times were calculated from exponential growth curve 
fits using GraphPad Prism.       
Western blotting 
Primary antibodies used for western blotting:  p-CHK1 S344 (#2341), p-CHK1 S296 (#2349), 
CHK1 (#2345), p-ATR S428 (#2853), CHK2 (#3440S), p-CHK2 T68 (#2661), Mre11 (#4847), 
p-Mre11 S676 (#4859), Rad50 (#3427), NBS (#3002), p-NBS S343 (#3001), CDK1 (#9112), 
CDK1 Y15 (#9111), Wee1 (#4936), p-Wee1 S642 (#4910), p-CDC25C T48 (#9527), all from 
Cell signalling; CDC25A (ab75743), ATM (ab2618), Nestin (ab22035), SOX2 (ab75485), all 
from Abcam; ATR (sc1887), PARP1 (sc8007), GAPDH (sc25778), all from Santa crud; p-
ATM S1981 (100-307) from Novus; CD133 (W6B3C1) from Miltenyi; γ-H2AX (JBW301) from 
Millipore; Olig2 (AF2418) from R&D systems and Actin (AC40) from Sigma.  
Flow cytometry and cell death 
For analysis of mitotic population, cells were treated and fixed with 70% ethanol and 
incubated with anti-phosphorylated Histone H3 serine 10 Alexa Fluor 488 conjugate antibody 
(1:50; Cell Signalling)  for 30 minutes followed by γ-H2AX Alexa 647 antibody (1:50; Cell 
Signalling) for 30 minutes at room temperature.  Cells were subsequently pelleted and 
resuspended in 1mg/ml propidium iodide (PI) containing RNAase A.  Dead cells and debris 
were gated out using FSC and SSC and doublets decimated using PI-area vs PI-width.  γ-
H2AX in mitotic cells was determined by gating on the mitotic population and presenting 
these events on a histogram plot.  Analysis of GSC markers CD133-PE (clone: 293C3) 
and CD15-APC (clone: VIMC6) was carried out according to manufactory instructions 
(Miltenyi biotech).  Flow cytometry was carried out using a FACScalibur or FACSVerse. 
 
